N@N

Biotech's Response to the MRSA Epidemic

^{Published on 2011-03-09 04:15:41 - Market Wire}
 

LOS ANGELES, CA--(Marketwire - March 9, 2011) - Staphylococcus aureus is a form of bacteria colonizing the skin and nostrils of up to 30 percent of the US population. A frequent cause of mild infections, it can become virulent when it gets inside the body. A variant known as Methicillin-resistant Staphylococcus aureus (MRSA) shows resistance against any beta-lactam antibiotic (i.e., penicillins, carbapenems, monobactams, and cephalosporins) as well as macrolides, streptogramins and lincosamides. In addition, MRSA exhibits emerging resistance to tetracycline, quinolones and sulfa drugs. Carried by at least 1.5 percent of the US population, MRSA is currently responsible for 19,000 deaths, 369,000 hospitalizations and seven million doctor/ER visits annually. It results in longer hospital stays and billions of dollars in additional healthcare costs.

A special report featuring a detailed look at the MRSA epidemic and its destructive potential has been published. The special Bio-Bulletin also examines different approaches that several biotech companies, including Emeryville, California-based NovaBay Pharmaceuticals (NYSE Amex: [ NBY ]), Baltimore, Maryland-based Intralytix Inc. and Sunnyvale, California-based, Cepheid have taken to developing treatments and a diagnostic test for it.

The full special report about the market opportunity facing these companies is now available at:

[ http://biomedreports.com/2011030964841/biotechs-response-to-the-mrsa-epidemic.html ]

Investors interested in accessing BioMedReports' complete database of clinical trials and upcoming FDA decisions can go to:

[ http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html ]

News developments and live healthcare sector updates are available constantly via twitter at: [ http://twitter.com/BioMedReports ]

About BioMedReports.Com

BioMedReports is a news portal covering the financial healthcare and biomedical sectors of the stock market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies and provides independent research to investors both free and via their subscription based model. Full disclosures and information is available in detail at BioMedReports.Com